NCT05364255View on ClinicalTrials.gov

A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 10, 2022

Primary Completion Date

June 20, 2022

Study Completion Date

June 20, 2022

Conditions
ER-positive, HER2-negative Breast Cancer
Interventions
DRUG

[14C]AZD9833 Oral Solution, 75 mg

Oral Solution, 75 mg (NMT 0.67 MBq) - oral, fasted

Trial Locations (1)

NG11 6JS

Research Site, Ruddington

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

lead

AstraZeneca

INDUSTRY